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ABSTRACT  
 
Immunoglobulin light chain (AL) amyloidosis is characterized by tissue deposition of amyloid 
fibers derived from immunoglobulin light chain. AL amyloidosis and multiple myeloma (MM) 
originate from monoclonal gammopathy of undetermined significance. We wanted to characterize 
germline susceptibility to AL amyloidosis using a genome-wide association study (GWAS) on 
1229 AL amyloidosis patients from Germany, UK and Italy, and 7526 healthy local controls. For 
comparison with MM, recent GWAS data on 3790 cases were used. For AL amyloidosis, single 
nucleotide polymorphisms (SNPs) at 10 loci showed evidence of an association at p<10
-5
 with 
homogeneity of results from the 3 sample sets; some of these were previously documented to 
influence MM risk, including the SNP at the IRF4 binding site. In AL amyloidosis, rs9344 at the 
splice site of cyclin D1, promoting translocation (11;14), reached the highest significance, p = 
7.80 x 10
-11
; the SNP was only marginally significant in MM. SNP rs79419269 close to gene 
SMARCD3 involved in chromatin remodeling was also significant (p=5.2x10
-8
). These data 
provide evidence for common genetic susceptibility to AL amyloidosis and MM. Cyclin D1 is a 
more prominent driver in AL amyloidosis than in MM, but the links to aggregation of light chains 
need to be demonstrated.  
  
 
 
 
 
INTRODUCTION 
 
Immunoglobulin light chain (AL) amyloidosis is a progressive disease often with a fatal 
outcome which affects around 3 per million of the population in Western countries 
1, 2
. The 
disease is characterized by the deposition of amyloid fibers derived from immunoglobulin light 
chain in multiple tissues leading to progressive organ failure. Characteristics of the amyloids 
relate to the disease severity and sequelae, including the target organs where amyloids 
accumulate, such as the heart, kidney, liver and peripheral nerves 
3
. Heart failure is usually the 
critical life-threatening condition which may ensue in a few months or years after diagnosis 
4
. 
Amyloidogenic light chains which contain the whole light chain or part of the variable domain 
are generally derived from clonal plasma cells unique to each patient 
3, 5
. Poor survival from AL 
is often related to late diagnosis 
6
. Monoclonal gammopathy of undetermined significance 
(MGUS) is the precursor condition for AL amyloidosis and multiple myeloma (MM) 
7
. About 
60% of MGUS constitute progressive disease, leading in 90% towards MM or other B-cell 
neoplasms and in 10% towards AL amyloidosis 
7, 8
; AL amyloidosis may also occur outside the 
context of MGUS. 
 
Three recent genome-wide association studies (GWASs) on MM identified 8 single nucleotide 
polymorphisms (SNPs) which were associated with the disease, including loci mapping to 
2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 5q15 (rs56219066), 6p21.33 
(rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077) and 22q13.1 (rs877529) 
9-11
. The 7 SNPs 
(except the one at 5q15) were tested on 443 AL amyloidosis patients and all were replicated at a 
nominal p<0.05 
12
. Translocation t(11;14) which was earlier shown to be influenced by the 
cyclin D1 splice site polymorphism (rs603965, also known as rs9344 which will be used here) in 
MM, was also found in AL amyloidosis with results identical to MM 
12, 13
. Importantly, t(11;14) 
is detected in more than 50% of the patients with AL amyloidosis 
14-17
 but in 20% or less of MM 
13
. Recently a large international pooling of GWAS data on MM was published, increasing the 
number of associated loci to 17 
18
. 
 
To explore the relationship between genetic susceptibility and the development of AL 
amyloidosis we performed a GWAS on 1229 German, UK and Italian patients and 7526 local 
controls. The results show that some genetic changes were shared between AL amyloidosis and 
MM but also suggest some unique genetic risk factors for AL amyloidosis.  
  
 
METHODS 
  
German AL amyloidosis patients were ascertained through the Amyloidosis Center at University 
Clinic Heidelberg. The UK samples were obtained from the National Amyloidosis Centre, 
London and the Italian samples came from the Amyloidosis Research and Treatment Center, 
Pavia. Informed consent and the appropriate approvals of the ethical
 
review boards of the 
respective universities were obtained for all subjects. Blood samples were drawn on newly 
diagnosed patients. IgM cases were not included due to their different biology. A total of 1351 
blood samples were available for analysis. The diagnosis of AL amyloidosis was made in 
accordance with standard criteria as described 
19
. Interphase fluorescence in situ hybridization 
(iFISH) data were available only in the German population. The methods for the assessment of 
IgH translocations t(11;14), t(4;14), t(14;16) and translocation with an unknown partner have 
been described 
20
. 
 
DNA was genotyped using Illumina Human OmniExpress-12 v1.0 arrays. General genotyping 
quality control assessment was carried out as previously described and all SNPs and samples 
presented in this study passed the set thresholds, including exclusion of population outliers by 
principal component analysis; however this was necessary only on German samples, adjusted for 
2 principal components 
9, 10
. The patient numbers after quality control were 562 (Germany), 410 
(UK) and 257 (Italy) (Table 1). Genotype frequencies were compared with control genotype data 
generated by the Heinz-Nixdorf Recall (HNR) study on 2147 German individuals, also used in 
the above MM studies; DNA was genotyped using Illumina HumanOmni1-Quad_v1 (707 
individuals) or Human OmniExpress -12v1.0 (1508 individuals) array. Italian healthy controls 
(n=413) were typed with the former array 
21
. The UK controls came from the UK Wellcome 
Trust Case Control Consortium 26 study on 5029 individuals typed using Illumina Human 1.2M-
Duo Custom_v1 
9, 10
. 
 
Genotypes for common variants across the genome in the three cohorts were imputed using data 
from the 1000 Genomes Project (phase 3, Oct. 2014) with IMPUTE2 v2.3.0 
22
 after pre-phasing 
with the SHAPEIT v2 r software 
23
. We set thresholds for imputation quality to retain both 
potential common and rare variants for validation. Specifically, poorly imputed SNPs defined by 
an information metric < 0.30 were excluded. All SNPs having a minor allele frequency (MAF) 
<1% were also excluded. The association test between imputed SNPs and AL amyloidosis was 
performed in SNPTESTv2.5 using the expected genotype counts 
24
. All three data sets were 
combined through an inverse variance meta-analysis under a fixed-effects model using the 
software GWAMA 
25
. All reported SNPs were confirmed by individual genotyping. All genomic 
locations are given in NCBI Build 37/UCSC hg19 coordinates. For genome-wide significance, a 
limit of p< 5x10
-8 
was used; a suggestive significance level of 10
-5
 was also considered. 
 
In order to test homogeneity of the results between AL amyloidosis and MM we performed a 
combined analysis using ASSET 
26
. This method explores all possible subsets for negative, 
positive, or null associations, identifying the subset with the strongest association signal; it also 
accounts for the multiple tests required by the subset analysis. The previously reported MM 
GWAS described the patient and control populations 
10
; these included 1508 German cases and 
2107 controls, and 2282 UK cases, independent from the AL cohorts, and 5197 controls. 
 
To investigate chromatin state segmentation profiles (ChromHMM) at risk loci we made use of 
the ENCODE project data on cell lines, including lymphoblastoid cells (GM12878) 
27
.  We also 
used HaploReg v4.1 (www.broadinstitute.org/mammals/haploreg) to evaluate the regulatory 
nature and the possible functional effects of SNPs and their proxies r
2
 ≥ 0.8, or 0.95 28.  All 
relevant data available in HaploReg were considered in the SNP search but when multiple cell 
types were listed data on hematologic cell types were reported. Association profiles were 
visualized using the Locuszoom 
29
 in conjunction with the UCSC genome browser 
27
.  
 
RESULTS  
 
Association analysis and comparison with MM 
A total of 1229 AL amyloidosis cases and 7526 controls passed the quality control filters for 
GWAS; the main characteristics of the patients did not essentially differ between the three centers 
(Table 1). Fig. 1 shows a Manhattan plot of the association meta-analysis with rs numbers for 10 
SNPs in loci for which more than one SNP reached a p-value below 10
-5
 (blue line in Fig. 1; red 
line is for genome-wide significance of 5x10
-8
). The most significant association was found on 
chromosome 11, represented by SNP rs9344. Other SNPs showing evidence of genome-wide 
significant associations were rs4487645 and rs79419269 both mapping to chromosome 7. The 
locus reaching a genome-wide significance level on chromosome 6 was based entirely on 
imputed SNPs and this was not considered further.  
 
For the 10 SNPs shown in Fig. 1 the risk alleles, ORs and heterogeneity of the results between the 
three centers (Phet and I
2
) are shown in Table 2. The OR was 1.35 for rs9344 (p= 7.80x10
-11
) on 
chromosome 11q13.3 and the results showed no heterogeneity between the three centers, also true 
for the other listed SNPs. Chromosome 7p15.3 SNP rs4487645 had an OR of 1.35 (p=1.80x10
-9
) 
and 7q36.1 SNP rs79419269 had an OR of 1.41 (p=5.2x10
-8
). rs1005300 on chromosome 22q13.1 
showed an OR of 1.29 (p=8.07x10
-8
). Some of the loci have already been published for MM: 
rs142802669 on chromosome 3p22.1 maps to the ULK4 gene, rs4487645 on chromosome 7p15.3 
maps to the binding site of IRF4, rs9344 is the splice site variant of cyclin D1 associated with the 
translocation t(11;14), rs4792800 on chromosome 17p11.2 maps to the intron of TNFRSF13B and 
rs1005300 on chromosome 22 maps to the CBX7 locus 
9, 10, 13, 30
. The present chromosome 17 and 
22 SNPs were not the same as the SNPs reported for MM but they were close and in linkage 
disequilibrium (LD, r
2
 0.96 and 0.56, respectively) with those reported. According to HaploReg, 
rs4792800 on chromosome 17p11.2 was only 2kb away and in high LD (r
2
 0.92) with rs34562254 
which is a missense variant in TNFRSF13B; however, this variant is predicted to be 
tolerated/benign in all transcripts by SIFT/PolyPhen. 
 
Table 2 shows also the respective SNP associations for MM among the German-UK MM patients 
(N = 3790) and controls (N = 7304). All ORs were higher among AL amyloidosis than MM 
patients, and the AL amyloidosis associated SNPs on chromosomes 1p36.13, 11q24.1 and 
14q13.2 were not significant in MM. For these SNPs and those at 7q36.1 and 11q13.3 the 95% 
confidence intervals (CIs) did not overlap between the AL amyloidosis and MM cohorts. We refer 
to these 5 SNPs operationally as ‘AL amyloidosis-specific associations’. 
 
We analyzed the homogeneity of the AL amyloidosis (3 data sets) and MM (2 data sets) cohorts 
using ASSET (Supplementary Figure 1). Chromosome 11q13.3 (rs9344) scored positive for AL 
amyloidosis data only. All associations which were earlier found in MM (chromosomes 3p22.1, 
7p15.3, 17p11.2 and 22q13.1) scored positive for all samples in the three amyloidosis sets, except 
that for the chromosome 17p11.2 SNP the German results were considered null. For the 
remaining SNPs, results in at least two amyloidosis sets were positive and no more than a single 
MM result was positive. The exception was the SNP at 11q24.1 (rs11219122) for which only the 
German amyloidosis result was positive. 
  
The newly reported 8 MM-related SNPs were tested for association in AL amyloidosis in 
Supplementary Table 1 
18
. For rs7781265 at 7q36.1 the OR and significance were higher for AL 
amyloidosis than for MM (1.41, 7.6x10
-8
 vs 1.20, 1.82x10
-7
; this SNP became genome-wide 
significant for MM after additional replication sets were included). 
 
Cytogenetic data were available only for 380 German patients on whom association analysis for 
rs9344 was performed separately on all patients and on those with and without t(11:14) and all 
IgH translocations (Table 3). t(11;14) accounted for 58% of all AL amyloidosis cases. The OR 
was 1.70 (p=4.7x10
-7
) for the risk allele G with t(11;14) and it was lower 1.50 (p=6.6x10
-6
) for 
cases with any IgH translocation. The OR was 1.14 (p=0.41) for IgH translocation other than 
t(11;14). We tested the associations of all other 9 SNPs from Table 2 with t(11:14) specific AL 
amyloidosis but no associations were found (data not shown). Homozygous GG individuals with 
t(11;14) accounted for 24% (93/380) of AL amyloidosis patients; among t(11;14) cases the OR 
was 3.52 for GG homozygotes against AA homozygotes compared to control genotypes.  
 
Biological interference 
 
HaploReg data on biological mechanisms for the 10 SNPs we summarized in Table 4. 
Additionally, regional plots of association results and ENCODE functional annotation are shown 
in Fig. 2 for 5 SNPs. Among amyloidosis-specific SNPs, rs10799599 on chromosome 1p36.13 is 
located between two phospholipase genes, within a region of high LD spanning the 3’end of the 
PLA2G2A gene (phospholipase A2, group IIA). This SNP and 7 highly linked SNPs (r
2
>0.8) are 
expression quantitative trait loci (eQTLs) in the liver for PLA2G2A at a p-value of 10
-8
, thus 
suggesting a possible mechanistic clue (footnote to Table 3). rs79419269 on chromosome 7q36.1 
maps to an intron of the SMARCD3 gene (SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily D, member 3), and it affects promotor and enhancer histone 
marks in many tissues and changes motifs of 5 transcription factors, including Foxp1 and 
HDAC2. According to ChromHMM the SNP is weakly transcribed in GM12878 cells and located 
next to a weak or poised enhancer. rs11219122 on chromosome 11q24.1 maps next to an RNA 
gene MIR4493 of unknown function. The SNP changes motifs for 10 transcription factors. As 
shown in Fig. 2 the SNP is located at a weakly transcribed locus next to a weak or poised 
enhancer.   
 
rs2273156 on chromosome 14q13.2 maps to a 100 kb linkage region and the SNP is intronic to an 
RNA gene (RP11-85K15.2) which is antisense to SRP54 (signal recognition particle 54kDa) (Fig. 
2 and Table 4). It is in high linkage with 67 SNPs of which 1/3 are intronic to SRP54.  According 
to HaploReg rs2273156 is a modest eQTL to SRP54 in transformed fibroblasts (p-value ~10
-5
) but 
it is a stronger eQTL in lymphoblastoid cells and whole blood to PPP2R3C (p-value up to 10
-14
), 
the protein phosphatase 2 regulatory subunit B gene (footnote to Table 3) . It is also an eQTL in 
lymphoblastoid cells to the next distal gene KIAA0391 (p-values up to 10
-10
), which is a part of 
mitochondrial ribonuclease P and functions in mitochondrial tRNA maturation. According to 
ChromHMM rs2273156 is located in a weakly transcribed sequence or at a transcriptional 
transition/elongation site depending on the cell line. SNPs linked to rs2273156 (r
2
>0.95) are listed 
in Supplementary Table 2. rs12890307 is in the 5’UTR and at an active promoter site of SRP54. 
This SNP is highly conserved and exhibits a multitude of functional changes. rs12890307 is 
eQTL to the above three genes, strongest to PPP2R3C (whole blood p-value 10
-198
)
31
.  
 
rs35629860 on chromosome 16p11.2 spans a linkage region of 200 kb and contains many genes 
with limited functional data (Fig.2, Table 4). rs35629860 is located at strong enhancer/active 
promoter sites in many cell types, including lymphoblastoid cells (Fig.2). The SNP is intronic to 
FBRS (fibrosin) and next to PRR14 (proline rich 14).  The linkage region includes RNF40 (ring 
finger protein 40, E3 ubiquitin protein ligase), SRCAP (Snf2-related CREBBP activator protein) 
and more distal BCL7C (B-cell CLL/lymphoma 7C). The SNP displays histone marks in many 
tissues and is an eQTL in 31 tissues and cell types; expression of RNF40 is affected in 10 tissues, 
including blood (p-value 10
-7
); the expression of PRR14 is affected in the skin (p-value 10
-7
) and 
of BCL7C in lymphoblastoid cells (p-value 10
-5
)(footnote to Table 4). rs35629860 is also an 
eQTL in several tissues to KAT8 (lysine acetyltransferase 8) which is located 0.5 Mb centromeric 
from the SNP. rs35629860 is flanked 5 kb away by rs3747481 (r
2
 0.95), a missense variant in 
PRR14, influencing expression of PRR14 in blood (p-value 10
-11
) and also an almost equally 
strong eQTL for RNF40 in blood (p-value 10
-10
) (Supplementary Table 3).  The missense variant 
is predicted by SIFT to be deleterious and by PolyPhen to be benign.  
 
DISCUSSION 
 
AL-amyloidosis is a rare disease for which genetic etiology is poorly understood, except that all 
the 7 SNPs first described in MM were replicated in AL amyloidosis with nominal p-values of 
<0.05 
12
. In the present study we identified 10 clusters of SNPs with p-values <10
-5
 for which 
the data from the three centers showed no evidence on heterogeneity and no confounding factors 
are known. When these were tested in the MM cohort all ORs were higher in AL amyloidosis 
than in MM and the 95%CIs for 5 SNPs did not overlap (‘AL-amyloidosis specific 
associations’), suggesting the existence of biological differences. However, for the 3 SNPs 
reaching a genome-wide significance of 5x10
-8
 only rs9344 was unique to AL amyloidosis. The 
OR for rs9344 (G/A870) on chromosome 11q13.3 was 1.35 (p-value 7.80x10
-11
) in AL 
amyloidosis vs. 1.06 in MM (p-value 0.04).  
 
The present data showed that the association of rs9344 was strongest (OR 1.70) in patients with 
t(11;14) while for other IgH aberrations the OR was only 1.14. Thus the high overall risk of 
rs9344 in AL amyloidosis is mainly explained by the high prevalence (58%) of t(11;14) 
compared to MM (20%) 
13
. Because of the high prevalence of t(11;14) and of the risk allele G 
(54%) there is a substantial group (24%) of AL amyloidosis patients with a combined high risk 
genotype (GG homozygosity and t(11;14)). Among t(11;14) specific AL amyloidosis the OR for 
GG homozygosity was 3.52 compared AA homozygosity. SNP rs9344 maps to a splice site in 
cyclin D1 for which the G allele is an optimal splice donor, encoding the full length protein D1a 
whereas allele A partially hinders splicing resulting in a shorter protein D1b 
32, 33
. In a previous 
study we showed that the levels of D1a and D1b transcript correlated with the GG, GA and AA 
genotypes in CD138-selected plasma cell 
13
. It is intriguing that the G allele encoding the full 
length D1a would be associated with AL amyloidosis or MM because it has a low transforming 
capacity compared to D1b 
34
. Cyclin D1 activation and translocation (11;14) are early pre-
MGUS events in plasma cell dyscrasias 
35, 36
. As the G allele is the risk factor for t(11;14) in AL 
amyloidosis and MM the D1a protein will promote the translocation which in turn would drive 
cyclin D1 expression by the IGH enhancers at the translocation locus. D1a may also act through 
separate pathways of promoting chromosomal aberrations because it is associated with double-
strand repair complexes of RAD51, BRCA1 and BRCA2 
37
. The influence of this splice site 
variant G/A870 on the risk of cancer has been tested in numerous case-control studies on many 
cancer types and most positive studies support a small risk for the A-allele in line with its 
transforming potential 
38, 39
. The present data suggest that the transformation pathway in plasma 
cell dyscrasias is routed via allele G and cyclin D1 activation with an important contribution by 
t(11;14), particularly in AL amyloidosis. 
 
Among the SNPs associated with both AL amyloidosis and MM rs4487645 on chromosome 
7p15.3 mapped within the binding site for interferon regulatory factor 4 (IRF4, alias myeloma 
oncogene 1) which is a strong enhancer for the adjacent gene CDCA7L 
30
. IRF4 is a critical 
transcriptional regulator in B-cell development, plasma cell survival and transformation through 
MYC 
40-43
. The SNPs on chromosomes 17p11.2 and 22q13.1 were in high LD with the ones 
reported for MM 
10
. rs4792800 on 17p11.2 mapped to the intron of TNFRSF13B, tumor necrosis 
factor receptor superfamily member 13B (alias TACI), a key regulator of B-cell development 
and homeostasis 
10
. rs1005300 on chromosome 22q13.1 is part of a 40kb LD region 
encompassing CBX7, the chromobox homolog 7 gene, which encodes a polycomb protein 
forming a part of polycomb repressive complex 1 
10
. Targeting CBX7 expression in the mouse 
lymphoid compartment induced the formation of aggressive B-cell lymphomas, in cooperation 
with MYC 
44
.  CBX7 regulates crucial genes involved in cancer progression and in epithelial-
mesenchymal transition, including osteopontin and E-cadherin 
44
. 
 
Among the AL amyloidosis-specific associations only rs79419269 on chromosome 7q36.1 with 
an OR of 1.41 reached a genome-wide significance of 5x10
-8
. However, this locus was marked 
by another SNP rs7781265 (r
2
=0.85) in the international pooling study on MM and the OR was 
somewhat higher (1.20) than that (1.14) for rs79419269 in MM in the present study 
(Supplementary Table 1) 
18
.  rs79419269 mapped to a 50 kb linkage region encompassing three 
genes ABCF2, a ATP-binding membrane transporter, CHPF2, chondroitin polymerizing factor 
and an RNA gene MIR671. It included also the 3’ part of the SMARCD3 gene, which encodes a 
member of the SWI/SNF family of proteins. These influence ATP dependent nucleosome 
remodeling, display helicase activity and may regulate transcription. SMARCD3 is involved in 
epithelial-mesenchymal transition by inducing Wnt5a signaling 
45
. In a GWAS on glycosylation 
levels of immunoglobulin G (IgG), which are thought to influence IgG effector functions, the 
present locus including SMARCD3 was one of the candidates 
46
.  
 
For the other AL amyloidosis associated SNPs we have to be cautious in speculating mechanisms 
because they did not reach a genome-wide significance. rs10799599 on chromosome 1p36.13 
displayed an eQTL in the liver for PLA2G2A, suggesting that this gene could be a functional 
explanation. The gene encodes an enzyme which has been associated with intestinal cancers and, 
more recently, as an inflammation-related prognostic marker in many tumors, including MM 
47
. 
AL amyloidosis-specific SNP (rs11219122) on chromosome 11q24.1 mapped next to an RNA 
gene MIR4493 of unknown function.  
 
Another amyloidosis-specific SNP (rs2273156) on chromosome 14q13.2 was in LD with SRP54 
which is a key signal recognition particle (SRP) protein escorting nascent secretory proteins from 
ribosomes to endoplasmic reticulum for secretion 
48, 49
. The SRP complex consists of a 7S RNA 
and 6 protein subunits: SRP9, SRP14, SRP19, SRP54, SRP68, and SRP72. Whether the SRP 
system functions in the secretion of M-protein in AL amyloidosis or MM is not known but signal 
recognition particle-dependent pathways are used in cells engineered to produce 
immunoglobulins 
50
. Moreover, the secretion of immunoglobulins from ribosomes to 
endoplasmic reticulum is obviously highly overloaded process in plasma cell dyscrasias 
42, 51
.  
rs2273156 and the linked SNPs displayed eQTL for SRP54 but also genes outside the linkage 
region, particularly for the PPP2R3C gene which encodes a regulatory subunit of the 
serine/threonine phosphatase, protein phosphatase 2. Homozygous knockout mice for PPP2R3C 
exhibit impaired proliferation of B cells suggesting that the gene is required for the B-cell 
receptor-mediated proliferation 
52
. This protein is also able to regulate the P-glycoprotein ATP-
binding cassette transporter through its phosphatase activity and influence drug responses to 
vincristine and doxorubicin 
53
. 
 
Many genes are in LD with rs35629860 on chromosome 16p11.2, including PRR14  which 
encodes a protein which tethers heterochromatin to nuclear lamina 
54
. Somatic mutations in 
PRR14 are found in human and animal tumors 
55
. Although rs35629860 display eQTL for several 
genes, including PRR14, RNF40 and KAT8, the linked missense variant in PRR14 may favor this 
gene as the mechanistic link. The adjacent SRCAP gene encodes a catalytic component of the 
chromatin-remodeling SRCAP complex. Srcap protein is an ATPase which functions by 
exchanging histone H2AZ/H2B dimers for nucleosomal H2A/H2B dimers. It is also an activator 
in Notch-mediated, CREB-mediated and steroid receptor-mediated transcription. Many cancer 
cell lines have mutations in SRCAP; Floating-Harbor syndrome and polycystic kidney disease 
are associated with germline mutations in this gene 
56, 57
. rs35629860 is in LD (r
2
=0.89) with 
rs8058578 which was found to provide suggested evidence for MM
18
. 
 
In conclusion, these data provide further evidence for shared inherited susceptibility between AL 
amyloidosis and MM. The association at cyclin D1 splice site variant G/A870 was much stronger 
in AL amyloidosis compared to MM which is explained by the higher prevalence of t(11;14)-
defined cases in AL amyloidosis and highlight the role of cyclin D1 and perhaps also of t(11;14) 
in the pathogenesis of AL amyloidosis. Two of the amyloidosis associated SNPs mapped close to 
chromatin remodeling genes, SMARCD3 on chromosome 7q36.1 and SRCAP or PRR14 on 
chromosome 16p11.2, which together with CBX7 on chromosome 22q13.1 suggest a functional 
importance. On chromosome 14q13.2 both candidates SRP54 and PPP2R3C could mediate B-cell 
related functions. Even if the present results define AL amyloidosis germline architecture akin to 
MM, the intriguing clue to the pathophysiology of AL amyloidosis may be the strong association 
with rs9344 at cyclin D1. While cyclin D1 is a driver in a majority of AL amyloidosis cases 
through t(11;14) the puzzling mechanistic question is whether the resulting stoichiometric excess 
of light chains promotes their aggregation.  
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FIGURES 
 
Fig. 1. Manhattan plot on meta- analysis of the 1230 AL-amyloidosis cases and 7589 regionally 
matched controls. rs numbers are shown for 10 SNPs in peaks with p-value below 10
-5
. 
The red horizontal line represents the significance thresholds of p = 5.0 × 10
−8
 and the blue horizontal 
line represents the significance thresholds of p = 1.0 × 10
-5
. 
 
 
  
Fig, 2. Regional plots of association and chromatin state segmentation profile for the SNPs associated 
with AL amyloidosis (a-e). Plots show results for 1p36.13 (rs10799599, a), 7q36.1 (rs79419269, b), 
11q24.1 (rs11219122, c), 14q13.2 (rs2273156, d) and 16p11.2 (rs35629860, e). The y axes show the 
−log10 (p-values) of the SNPs and the x axes show their chromosomal positions. The top associated 
SNP is shown as a purple diamond and is labeled by its rsID. The color intensity of each symbol 
represents the strength of LD with the top SNP. Genetic recombination rates (cM/Mb) are indicated 
with a light blue line. The lower track shows the chromatin-state segmentation track (ChromHMM) for 
lymphoblastoid cells from the HapMap ENCODE Project. 
TABLES 
 
Table 1: Demographic and clinical characteristics of the AL amyloidosis patients from the three centers. 
 
 German British Italian All populations 
Sample size, N 562 410 257 1229 
Age at diagnosis     
Median age (years; range) 62 (34.3-84.8) 65 (29.5-86.8) 65 (38.1-87.1)  64 (29.5-87.1) 
Gender     
Males 324 (58%) 241 (59%) 146 (57%) 710 (58%) 
Females 239 (42%) 170 (41%) 111 (43%) 520 (42%) 
Number of organs involved     
No Organ   27 (5%) 17 (4%)    5   (2%) 49 (4%) 
One organ  254 (45%) 198 (48%) 116 (45%) 568 (46%) 
Two organs 237 (42%) 167 (41%) 126 (49%) 530 (43%) 
Three organs  45 (8%)  28 (7%)  10 (4%) 83 (7%) 
Type of organ involveda     
Kidney 359 (64%) 320 (78%) 166 (65%) 845 (69%) 
Heart 397 (71%) 239 (58%) 200 (78%) 836 (68%) 
Liver 106 (19%)   57 (14%)  32 (12%) 195 (16%) 
Missing Data - 18  - 18  
Antibody isotypes     
Lambda (L) 438 (78%) 304 (80%) 188 (73%) 930 (78%) 
Kappa (K) 123 (22%) 74 (20%)  69 (27%) 266 (22%) 
Light-chains only: L or K 312 (55%) 95 (29%)   127 (49.5%) 534 (47%) 
Light-chains & heavy-chains 249 (44%) 233 (71%)   130 (50.5%) 612 (53%) 
Missing data on light-chains      1   32 - 33  
Missing data on heavy-chains      1  82  - 83  
a 
: The sum of the percentages exceeds 100 because in many patients multiple organs were involved. 
 Table 2: Top SNPs in the meta-analysis of amyloidosis considering German (DE), UK and Italian (IT) GWAS. Also shown are 
respective associations for MM. 
SNP CHR BP A B
a
 
Amyloidosis Meta-analysis (DE + UK + IT) Meta Myeloma DE + UK 
RAF
b
 OR (95% CI)
c
 P Phet
d
 I
2e
 RAF
b
 OR (95% CI)
c
 P 
rs10799599 1p36.13 20294500 G C 0.62 1.26 (1.15 - 1.39) 1.05 x 10
-6
 0.21 0.36 0.62 1.01 (0.95 - 1.07) 0.71 
rs142802669 3p22.1 41869427 A C 0.17 1.30 (1.16 - 1.45) 3.15 x 10
-6
 0.34 0.08 0.17 1.28 (1.19 - 1.38) 1.62 x 10
-11
 
rs4487645 7p15.3 21938240 A C 0.67 1.35 (1.22 - 1.49) 1.80 x 10
-9
 0.42 0.00 0.70 1.28 (1.21 - 1.36) 1.56 x 10
-15
 
rs79419269 7q36.1 150937076 T C 0.12 1.41 (1.25 - 1.60) 5.20 x 10
-8
 0.96 0.00 0.12 1.14 (1.05 - 1.24) 2.44 x 10
-3 
rs9344 11q13.3 69462910 A G 0.56 1.35 (1.23 - 1.48) 7.80 x 10
-11
 0.21 0.36 0.54 1.06 (1.00 - 1.12) 4.00 x 10
-2
 
rs11219122 11q24.1 123240173 T C 0.35 1.25 (1.14 - 1.37) 1.91 x 10
-6
 0.05 0.66 0.35 1.00 (0.94 - 1.06) 0.97 
rs2273156 14q13.2 35438799 T C 0.19 1.29 (1.16 - 1.44) 2.88 x 10
-6
 0.14 0.50 0.18 1.02 (0.95 - 1.10) 0.55 
rs35629860 16p11.2 30671532 G A 0.26 1.26 (1.14 - 1.39) 3.87 x 10
-6
 0.99 0.00 0.26 1.13 (1.06 - 1.20) 2.45 x 10
-4
 
rs4792800 17p11.2 16845167 A G 0.12 1.36 (1.20 - 1.54) 2.27 x 10
-6
 0.12 0.53 0.12 1.25 (1.15 - 1.36) 3.12 x 10
-7
 
rs1005300 22q13.1 39547891 C G 0.59 1.29 (1.17 - 1.41) 8.07 x 10
-8
 0.95 0.00 0.61 1.25 (1.18 - 1.32) 5.81 x 10
-14
 
 
a - B is the risk allele; b - risk allele frequency; c – OR odds ratio, CI confidence interval; d - p-value derived from Cochran's Q 
heterogeneity test; e - proportion of total variance that is due to heterogeneity (I
2
). 
  
Table 3: Risk of AL amyloidosis in Germans, overall and by cytogenetic subtype, considering rs9344 genotypes.  
 
 
 
 
 
 
a – 
frequency 
of risk allele G; b – OR odds ratio, CI confidence interval 
 
  
Cytogenetic subtypes RAF
a
 
Cases Controls 
OR (95% CI)
b
 P 
AA GA GG total AA GA GG total 
AL amyloidosis 0.56 71 282 209 562 459 1049 639 2147 1.39 (1.22 - 1.60) 2.00 x 10
-6
 
t11;14 positive 0.55 19 110 93 222 459 1049 639 2147 1.70 (1.38 - 2.09) 4.70 x 10
-7
 
IgH positive 0.55 33 160 121 313 459 1049 639 2147 1.50 (1.26 - 1.79) 6.60 x 10
-6
 
t11;14 negative 0.54 27 80 51 158 459 1049 639 2147 1.14 (0.91 - 1.44) 0.22 
IgH negative 0.54 13 30 23 67 459 1049 639 2147 1.15 (0.81 - 1.62) 0.38 
IgH positive and  
t11;14 negative 
0.54 14 49 28 91 459 1049 639 2147 1.14 (0.84 - 1.54) 0.41 
Table 4. HaploReg v4.1 annotation of the 10 candidate SNPs for AL amyloidosis. 
 
SNP CHR SNPs 
r2>0.8a  
Promoter 
histone 
marksb 
Enhancer 
histone 
marksc 
DNAse Proteins 
bound 
Motifs 
changed 
Selected 
eQTL hits 
GENCODE genes dbSNP func 
annot 
rs10799599 1 7 muscle 5 tissues 8 
tissues 
 4 altered 
motifs 
liverd 3kb 5' of 
Metazoa_SRP 
 
rs142802669 3 2      31 hits ULK4 intronic 
rs4487645 7 9 2 tissues 10 tissues 10 
tissues 
IRF4,PU1  blood DNAH11 intronic 
rs79419269 7 - 9 tissues 13 tissues skin  5 altered 
motifs 
 SMARCD3 intronic 
rs9344 11 - 14 tissues 15 tissues 9 
tissues 
PAX5C20,POL2 4 altered 
motifs 
 CCND1 synonymous 
splice site 
rs11219122 11 4     10 altered 
motifs 
 12kb 3' of 
MIR4493 
 
rs2273156 14 67 lung 3 tissues   Foxj1,STAT 28 hitse RP11-85K15.2 intronic 
rs35629860 16 22 18 tissues 23 tissues 18 
tissues 
5 bound 
proteins 
CCNT2 31 hitsf FBRS  
rs4792800 17 17 3 tissues 4 tissues 11 
tissues 
 12 altered 
motifs 
 TNFRSF13B intronic 
rs1005300 22 24 16 tissues 18 tissues 9 
tissues 
HNF4A 5 altered 
motifs 
2 hits CBX7 intronic 
a 
based on 1000 Genomes Phase 1 data. 
b 
enrichment of H3K4me3/H3K9ac histone marks. 
c
 enrichment of H3K4me1/H3K27ac histone marks. 
d 
eQTL in the liver for PLA2G2A at p=2.5x10
-8
. 
e 
eQTL in transformed fibroblasts for SRP54 at p=1.6x10
-5
, in whole blood for IGBP1P1 at p=8.9x10
-7
, in whole blood for PPP2R3C 
at 1.1x10
-14
, and in lymphoblastoid cells for PPP2R3C at p=1.3x10
-5
-3.8x10
-11
 and for KIAA0391 at p=6.3x10
-6
-5.1x10
-10
. 
f 
eQTL in blood for RNF40 at p=9.8x10
-8
, in skin for PRR14 at p=2.9x10
-7
, in lymphoblastoid cell for BCL7C at p=1.5x10
-5
, in thyroid 
for c16orf93 (CCDC193) at p=7.8x10
-14
 and in artery wall for KAT8 at p=6.1x10
-10
. 
 
  
 Supplementary information 
 
Supplementary Table 1. Results for 8 SNPs identified in a new meta-analysis for multiple myeloma (Mitchell et al. 2016, ref. 18). 
 
 
SNP CHR BP A B
a
 
Amyloidosis Meta-analysis (DE + UK + IT) Meta Multiple Myeloma 
RAF
b
 OR (95% CI)
c
 P-value Phet
d
 I
2e
 RAF
b
 OR (95% CI)
c
 P-value 
rs34229995 6p22.3 15244018 C G 0.02 1.41 (1.09 - 1.84) 0.01 0.88 0.00 0.03 1.40 (1.25 - 1.58) 1.76 × 10
−8
 
rs9372120 6q21 106667535 T G 0.20 1.11 (0.99 - 1.24) 0.06 0.47 0.00 0.22 1.20 (1.14 - 1.26) 8.72 × 10
−14
 
rs7781265 7q36.1 150950940 G A 0.12 1.41 (1.24 - 1.59) 7.6 × 10
−8
 0.81 0.00 0.13 1.20 (1.12 - 1.29) 1.82 × 10
−7
 
rs1948915 8q24.21 128222421 T C 0.33 1.03 (0.94 - 1.14) 0.48 0.48 0.00 0.35 1.14 (1.10 - 1.19) 3.14 × 10
−10
 
rs2811710 9q21.3 21991923 T C 0.64 1.10 (1.00 - 1.21) 0.04 0.23 0.32 0.66 1.14 (1.09 - 1.19) 6.5 × 10
−10
 
 a
 - allele B is the risk allele; 
b 
- risk allele frequency; 
c
 - 95% confidence interval; 
d
 - p-value derived from Cochran's Q heterogeneity test; 
e
 - proportion of 
total variance that is due to heterogeneity (I
2
). 
 
 
 
 
 
 
rs2790457 10p12.1 28856819 A G 0.73 1.05 (0.95 - 1.16) 0.34 2.4 × 10
−3
 0.83 0.74 1.12 (1.07 - 1.17) 8.44 × 10
−7
 
rs7193541 16q23.1 74664743 C T 0.59 1.12 (1.02 - 1.22) 0.02 0.13 0.50 0.59 1.12 (1.08 - 1.17) 1.14 × 10
−8
 
rs6066835 20q13.13 47355009 T C 0.08 1.12 (0.95 - 1.31) 0.17 0.43 0.00 0.08 1.24 (1.16 - 1.33) 1.16 × 10
−9
 
Supplementary Table 2. HaploReg v4.1 annotation of SNPs in high LD (r
2
 >0.95) with rs2273156 at 14q13.2. 
 
 
a 
Abbreviations: BLD blood, MUS muscle, LNG lung, BRST breast, ESC esophagus, SPLN spleen, HRT heart.  
b
 eQTL in blood for PPP2R3C at p=9.8x10
-198
, for SRP54 at p=2.0x10
-27
 and for KIAA0391 at p=4.0x10
-6
-3.7x10
-10
. 
 
 
 
 
  
SNPs pos (hg38) LD (r²) Ref Alt 
EUR 
freq 
Promoter 
histone marks 
Enhancer 
histone marks 
DNAse Proteins bound Motifs changed 
Selected 
eQTL hits 
GENCODE 
genes 
dbSNP             
func annot 
rs35106382 34965085 0.98 T C 0.19 BLD, MUSa BLD, SKIN BLD 
 
ERalpha-a,LRH1,Maf 29 hits RP11-85K15.2 intronic 
rs8014327 34965530 0.98 C T 0.19 BLD, MUS 3 tissues HRT 
 
Foxj2,Maf 32 hits RP11-85K15.2 intronic 
rs12894365 34966185 0.98 C A 0.19 3 tissues 4 tissues BLD POL2 Pou6f1 32 hits RP11-85K15.2 intronic 
rs12894820 34966319 0.98 G A 0.19 3 tissues 5 tissues 
 
GATA1 LUN-1 32 hits RP11-85K15.2 intronic 
rs2273156 34969593 1 T C 0.19 LNG 4 tissues 
  
Foxj1,STAT 28 hits RP11-85K15.2 intronic 
rs12893021 34971474 0.98 A C 0.19 3 tissues 11 tissues BRST,SKIN CFOS 7 altered motifs 28 hits RP11-85K15.2 intronic 
rs17102904 34971843 0.97 G T 0.19 3 tissues 12 tissues 5 tissues 
 
CCNT2,TAL1,TCF4 28 hits RP11-85K15.2 intronic 
rs76472781 34973178 0.98 C G 0.19 
 
5 tissues 
   
29 hits RP11-85K15.2 intronic 
rs12895051 34974864 0.98 G A 0.19 
 
BLD 
  
GR 33 hits RP11-85K15.2 intronic 
rs35090385 34975229 0.96 T G 0.19 BRST BLD, SPLN 
  
Pdx1 28 hits RP11-85K15.2 intronic 
rs71421920 34977539 0.98 T C 0.19 BLD 4 tissues 
  
6 altered motifs 28 hits RP11-85K15.2 intronic 
rs8019179 34978589 0.98 T C 0.19 BLD, ESC 4 tissues LNG 
 
4 altered motifs 30 hits RP11-85K15.2 intronic 
rs17102923 34980633 0.98 G A 0.19 19 tissues 23 tissues 
  
Evi-1,Hand1,SIX5 30 hits RP11-85K15.2 intronic 
rs34678475 34981897 0.96 T A 0.19 24 tissues 23 tissues 36 tissues CTCF,POL2 Pou5f1,Sox 30 hits RP11-85K15.2 intronic 
rs12890307 34982926 0.95 G A 0.19 24 tissues 23 tissues 53 tissues 34 bound proteins 4 altered motifs 34 hitsb SRP54 5'-UTR 
  
Supplementary Table 3. HaploReg v4.1 annotation of SNPs in high LD (r
2
 >0.95) with rs35629860 at 16p11.2. 
 
 
a
 eQTL in blood for PRR14 at p=7.2x10
-11
 and in blood and other tissues for e.g., RNF40, C16orf93 (CCDC193) and KAT8. 
 
 
 
 
 
 
 
 
 
SNPs pos (hg38) LD (r²) Ref Alt 
EUR 
freq 
Promoter 
histone marks 
Enhancer 
histone marks 
DNAse Proteins bound Motifs changed 
Selected 
eQTL hits 
GENCODE 
genes 
dbSNP             
func annot 
rs3747481 30655046 0.95 C T 0.28 
 
13 tissues Blood 
 
8 altered motifs 38 hitsa PRR14 missense 
rs35629860 30660211 1 G A 0.27 24 tissues 23 tissues 18 tissues 5 bound proteins CCNT2 31 hits FBRS 
 
rs67128646 30660776 1 A C 0.27 19 tissues 24 tissues 13 tissues 6 bound proteins Foxi1,Foxj2,VDR 30 hits         FBRS  
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Supplementary Figure 1. 1 
SNP ASSET analysis of SNPs considering amyloidosis by the 3 centers and multiple myeloma results 2 
from Germany and UK. 3 
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